Imaging software developer Median Technologies has signed a collaboration agreement with Memorial Sloan Kettering Cancer Center in New York City.
Median's iBiopsy system will be used for a retrospective study at the cancer center of MR images of 200 patients who underwent radical prostatectomy after being diagnosed with prostate cancer and for whom histological slides and analyses are available. The study will explore the use of automated texture analysis and machine learning provided by Median iBiopsy to classify lesions on MRI in terms of aggressiveness.
